A Novel GLP-1/FGF21 Dual Agonist ZT003 Has Therapeutic Potential for Obesity, Diabetes, and Nonalcoholic Steatohepatitis

被引：0
|
作者：
Zhang, Yuanyuan
Zhang, Yuying
Zhao, Chunlai
Lin, Simei
Guo, Wei
Wu, Bo
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-297-OR
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
297-OR
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A novel GLP-1/FGF21 dual agonist ZT003 has therapeutic potential for obesity, MASH and SHTG
    Zhang, Y.
    Zhang, Y.
    Zhao, C.
    Lin, S.
    Guo, W.
    Wu, B.
    DIABETOLOGIA, 2024, 67 : S541 - S541
  • [2] A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis
    Pan, Qi
    Lin, Shushan
    Li, Yu
    Liu, Liang
    Li, Xiaoping
    Gao, Xianglei
    Yan, Jiangyu
    Gu, Baohua
    Chen, Xiaofeng
    Li, Wenjia
    Tang, Xinfa
    Chen, Chao
    Guo, Lixin
    EBIOMEDICINE, 2021, 63
  • [3] Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis
    Ye, Xianlong
    Chen, Yingli
    Qi, Jianying
    Zhu, Shenglong
    Wu, Yuanyuan
    Xiong, Jingjing
    Hu, Fei
    Guo, Zhimou
    Liang, Xinmiao
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 952
  • [4] YH25724, a novel long-acting GLP-1/FGF21 dual agonist improves hepatic steatosis, inflammation and fibrosis in nonalcoholic steatohepatitis (NASH) animal models
    Kim, Jun Hwan
    Hong, Han Na
    Choi, Hyun Ho
    Kim, Dohoon
    Kim, Tae Wang
    Lim, Seyoung
    Seo, Minji
    Ju, Mi Kyeong
    Park, Ju-Young
    Choi, Byung Hyun
    Tolbol, Kirstine S.
    Feigh, Michael
    Vrang, Niels
    Kim, Jong Gyun
    Nam, Su Youn
    HEPATOLOGY, 2016, 64 (06) : 1136A - 1137A
  • [5] Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia
    Gilroy, C. A.
    Capozzi, M. E.
    Varanko, A. K.
    Tong, J.
    D'Alessio, D. A.
    Campbell, J. E.
    Chilkoti, A.
    SCIENCE ADVANCES, 2020, 6 (35):
  • [6] A Novel GLP-1 and FGF-21 Dual Agonist Drug Protects Mice from Obesity and Hyperglycemia
    Gilroy, Caslin A.
    Capozzi, Megan
    Su, Jonathan C.
    Tong, Jenny
    D'Alessio, David A.
    Campbell, Jonathan
    Chilkoti, Ashutosh
    DIABETES, 2019, 68
  • [7] Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
    Hartman, Mark L.
    Sanyal, Arun J.
    Loomba, Rohit
    Wilson, Jonathan M.
    Nikooienejad, Amir
    Bray, Ross
    Karanikas, Chrisanthi A.
    Duffin, Kevin L.
    Robins, Deborah A.
    Haupt, Axel
    DIABETES CARE, 2020, 43 (06) : 1352 - 1355
  • [8] Design of a Dual Agonist of Exendin-4 and FGF21 as a Potential Treatment for Type 2 Diabetes Mellitus and Obesity
    Zhang, Changzhen
    Gao, Guosheng
    Li, Yafeng
    Ying, Jingjing
    Li, Jianhui
    Hu, Supei
    IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH, 2023, 22 (01):
  • [9] The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis
    Kayed, Ashref
    Melander, Simone Anna
    Khan, Suheb
    Andreassen, Kim Vietz
    Karsdal, Morten Asser
    Henriksen, Kim
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 384 (03): : 406 - 416
  • [10] Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review
    Mahapatra, Manoj K.
    Karuppasamy, Muthukumar
    Sahoo, Biswa M.
    PHARMACEUTICAL RESEARCH, 2022, 39 (06) : 1233 - 1248
12345